Filing Flows

Filing Flows › Companies › Orchestra BioMed Holdings › Cash flow

Orchestra BioMed Holdings cash flow, quarter by quarter

Latest: Q2 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$19.6M in Q2 2026 · −$59.1M over twelve months

Operating cash flow−$19.3M
Capital spending−$254K
Free cash flow−$19.6M
Cash conversion cycle-21621 days

Analysis

In Q2 2026, Orchestra BioMed Holdings generated −$19.3M of operating cash flow and spent $254K on capital projects, leaving free cash flow of −$19.6M. That is $4.0M less than in Q2 2025 (−$15.6M).

Over the twelve months to Jun 30, 2026, operating cash flow was −$58.3M; the largest uses were other investing ($68.5M), operating cash flow ($58.3M), taxes on employees’ shares ($1.4M); besides operations, cash came from other financing ($131M), shares issued ($34K); the cash balance rose by $1.7M.

Operating cash flow was −$19.3M against net income of −$23.8M. The largest differences: stock-based pay +$2.5M, prepaid and other assets +$491K, payables −$253K.

Its cash conversion cycle was -21621 days (receivables 70 + inventory 959 − payables 22650): suppliers fund its working capital.

Free cash flow

Orchestra BioMed Holdings: free cash flow by quarterOrchestra BioMed Holdings: free cash flow by quarter−$13.8MQ3 2024−$13.6MQ4 2024−$16.7MQ1 2025−$15.6MQ2 2025−$14.9MQ3 2025−$2.3MQ4 2025−$22.4MQ1 2026−$19.6MQ2 2026
Operating cash flow less capital spending.
Orchestra BioMed Holdings: operating cash flow against capital spendingOrchestra BioMed Holdings: operating cash flow against capital spendingOperating cash flowCapital spending−$13.7M$68KQ3 2024−$13.5M$106KQ4 2024−$16.6M$112KQ1 2025−$15.5M$34KQ2 2025−$14.6M$310KQ3 2025−$2.3M$33KQ4 2025−$22.2M$184KQ1 2026−$19.3M$254KQ2 2026
Latest (Q2 2026): Operating cash flow −$19.3M, Capital spending $254K.

Capital allocation, year by year

Orchestra BioMed Holdings: where the cash came from (up) and went (down), by fiscal yearOrchestra BioMed Holdings: where the cash came from (up) and went (down), by fiscal yearOperating cash flowNet borrowingShares issuedCapital spendingDividendsFY2021: Operating cash flow −$272KFY2021FY2022: Operating cash flow −$29.3MFY2022: Net borrowing $3.6MFY2022: Shares issued $110MFY2022: Capital spending −$591KFY2022: Dividends −$20.0M$114MFY2022FY2023: Operating cash flow −$46.1MFY2023: Net borrowing −$10.8MFY2023: Shares issued $231KFY2023: Capital spending −$78K$231KFY2023FY2024: Operating cash flow −$50.6MFY2024: Net borrowing $15.0MFY2024: Shares issued $240KFY2024: Capital spending −$289K$15.2MFY2024FY2025: Operating cash flow −$49.0MFY2025: Shares issued $91KFY2025: Capital spending −$489K$91KFY2025
Over these 5 years operating cash flow totalled −$175M; the largest uses were operating cash flow ($175M) and dividends ($20.0M). Cash-flow statements as filed.

Cash runway and the debt wall

Cash & investments$110M
Debt$15.0M
Net cash$95.0M
Cash runway22 months

Orchestra BioMed Holdings is burning cash: its operations consume cash, a free cash flow of −$59.1M a year at the current rate against $110M of cash and investments: a runway of about 22 months before any new financing.

Orchestra BioMed Holdings: debt maturities by year (FY2025)Orchestra BioMed Holdings: debt maturities by year (FY2025)$5.1MYear 2$9.9MYear 3
Principal due in each year as disclosed in the annual report, against $110M of cash and investments now.

Where the cash came from and went

Orchestra BioMed Holdings: sources (+) and uses (−) of cash, Q2 2026Orchestra BioMed Holdings: sources (+) and uses (−) of cash, Q2 2026Other financing$35.0MOther investing−$23.1MOperating cash flow−$19.3MCash drawn (+) / kept (−)$7.9MTaxes on employees’ shares−$262KCapital spending−$254KShares issued$8K
Orchestra BioMed Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Orchestra BioMed Holdings: sources (+) and uses (−) of cash, TTM to Q2 2026Other financing$131MOther investing−$68.5MOperating cash flow−$58.3MCash drawn (+) / kept (−)−$1.7MTaxes on employees’ shares−$1.4MCapital spending−$781KShares issued$34K

From profit to cash

Orchestra BioMed Holdings: net income to operating cash flow, Q2 2026Orchestra BioMed Holdings: net income to operating cash flow, Q2 2026Net income−$23.8MDepreciation & amortization$96KStock-based pay$2.5MGains on investments−$45KReceivables$33KInventory$27KPayables−$253KPrepaid and other assets$491KOperating cash flow−$19.3M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.
QuarterReceivable daysInventory daysPayable daysCash conversion cycle
Q2 20267095922650-21621
Q1 20267382517449-16550
Q4 2025060913140-12531
Q3 2025751612937-12414
Q2 2025931710753-10427
Q1 2025931510940-10616
Q4 2024383237818-7457
Q3 202492067438-7224

Every quarter

QuarterOperating cash flowCapital spendingShares issuedCash drawn (+) / kept (−)Free cash flow
Q2 2026−$19.3M−$254K$8K$7.9M−$19.6M
Q1 2026−$22.2M−$184K$26K$6.3M−$22.4M
Q4 2025−$2.3M−$33K—$7.3M−$2.3M
Q3 2025−$14.6M−$310K—−$23.3M−$14.9M
Q2 2025−$15.5M−$34K—−$401K−$15.6M
Q1 2025−$16.6M−$112K$91K$3.9M−$16.7M
Q4 2024−$13.5M−$106K$51K$3.3M−$13.6M
Q3 2024−$13.7M−$68K—−$1.9M−$13.8M

Orchestra BioMed Holdings: income statement and cash flow

Orchestra BioMed Holdings, Q2 2026: revenue $88K (-90% year over year). The chart follows the revenue to costs, profit and cash.

Orchestra BioMed Holdings: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.